Immunovant Inc (NASDAQ:IMVT)’s traded shares stood at 0.46 million during the latest session, with the company’s beta value hitting 0.67. At the last check today, the stock’s price was $20.57, to imply an increase of 1.01% or $0.21 in intraday trading. The IMVT share’s 52-week high remains $39.55, putting it -92.27% down since that peak but still an impressive 1.75% since price per share fell to its 52-week low of $20.21. The company has a valuation of $3.49B, with an average of 1.52 million shares in intraday trading volume over the past 10 days and average of 1.08 million shares over the past 3 months.
Analysts have given a consensus recommendation of Buy for Immunovant Inc (IMVT), translating to a mean rating of 1.15. Of 20 analyst(s) looking at the stock, 1 analyst(s) give IMVT a Sell rating. 0 of those analysts rate the stock as Overweight while 6 advise Hold as 13 recommend it as a Buy. 0 analyst(s) have given it an Underweight rating. Estimates put the company’s current-quarter earnings per share at -0.73.
Immunovant Inc (NASDAQ:IMVT) trade information
After registering a 1.01% upside in the latest session, Immunovant Inc (IMVT) has traded red over the past five days. The 5-day price performance for the stock is -5.40%, and -16.53% over 30 days. With these gigs, the year-to-date price performance is -16.97%. Short interest in Immunovant Inc (NASDAQ:IMVT) saw shorts transact 12.83 million shares and set a 12.19 days time to cover.
The extremes give us $51 and $51 for target low and target high price respectively. As such, IMVT has been trading -147.93% off suggested target high and -147.93% from its likely low.
Immunovant Inc (IMVT) estimates and forecasts
Looking at statistics comparing Immunovant Inc share performance against respective industry, we note that the company has underperformed competitors. Immunovant Inc (IMVT) shares are -23.77% down over the last 6 months, with its year-to-date growth rate lower than industry average at -53.93% against 16.00%.
IMVT Dividends
Immunovant Inc has its next earnings report out in March. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too.
Immunovant Inc (NASDAQ:IMVT)’s Major holders
Immunovant Inc insiders hold 58.10% of total outstanding shares, with institutional holders owning 47.06% of the shares at 112.31% float percentage. In total, 47.06% institutions holds shares in the company, led by FMR LLC. As of 2024-06-30, the company held over 10.48 million shares (or 7.5915% of shares), all amounting to roughly $276.77 million.
The next major institution holding the largest number of shares is VANGUARD GROUP INC with 6.51 million shares, or about 4.7138% of shares outstanding. As of the market price on 2024-06-30, these shares were worth $171.86 million.
We also have Fidelity Growth Company Fund and Vanguard Total Stock Market Index Fund as the top two Mutual Funds with the largest holdings of the Immunovant Inc (IMVT) shares. Going by data provided on Nov 30, 2024 , Fidelity Growth Company Fund holds roughly 3.49 shares. This is just over 2.05% of the total shares, with a market valuation of $71.31 million. Data from the same date shows that the other fund manager holds a little less at 2.12, or 1.25% of the shares, all valued at about 43.29 million.
